title: The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.
abstract: Modulation of the low affinity adenosine receptor subtype, the A2b adenosine receptor (A2bAR), has gained interest as a therapeutic target in various pathologic areas associated with cardiovascular disease. The actions of the A2bAR are diverse and at times conflicting depending on cell and tissue type and the timing of activation or inhibition of the receptor. The A2bAR is a promising and exciting pharmacologic target, however, a thorough understanding of A2bAR action is necessary to reach the therapeutic potential of this receptor. This review will focus on the role of the A2bAR in various cardiovascular and metabolic pathologies in which the receptor is currently being studied. We will illustrate the complexities of A2bAR signaling and highlight areas of research with potential for therapeutic development.
authors.affiliation: Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.|Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Anna
authors.initials: A
authors.lastname: Eisenstein
authors.affiliation: Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.|Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Shenia
authors.initials: S
authors.lastname: Patterson
authors.affiliation: Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.|Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts.|Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts.|Evans Center for Interdisciplinary Biomedical Research, Boston University School of Medicine, Boston, Massachusetts.
authors.forename: Katya
authors.initials: K
authors.lastname: Ravid
mesh_terms: D058908:Adenosine A2 Receptor Agonists / Q000627:therapeutic use; D058917:Adenosine A2 Receptor Antagonists / Q000627:therapeutic use; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D043704:Receptor, Adenosine A2B / Q000187:drug effects / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D058908:Adenosine A2 Receptor Agonists; D058917:Adenosine A2 Receptor Antagonists; D002317:Cardiovascular Agents; D043704:Receptor, Adenosine A2B